Immunovaccine Announces Achievement of Milestones in Collaboration with Zoetis to Develop Veterinary Vaccines
August 31 2017 - 7:05AM
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage
immuno-oncology company, today announced the achievement of several
milestones in its ongoing collaboration with global animal health
company Zoetis to develop cattle vaccines. In recent controlled
studies, the Immunovaccine formulations met efficacy and duration
of immunity endpoints against two disease targets. These results
will enable Zoetis to advance two Immunovaccine-formulated vaccine
candidates into late-stage testing.
“We are extremely pleased with the recent progress
of our long-standing collaboration with Zoetis, and the
continuation of these vaccine candidates into later-stage testing,”
said Frederic Ors, Immunovaccine’s Chief Executive Officer. “Our
development platform continues to exceed our expectations,
repeatedly demonstrating that its unique mechanism of action can
translate into meaningful efficacy and clinical benefits across
multiple indications.”
Immunovaccine has had an ongoing licensing
agreement with Zoetis since 2008 to leverage Immunovaccine’s
proprietary vaccine delivery technology in enhanced vaccines for
the cattle industry.
About ImmunovaccineImmunovaccine
Inc. is a clinical stage biopharmaceutical company dedicated to
making immunotherapy more effective, more broadly applicable, and
more widely available to people facing cancer and other serious
diseases. Immunovaccine develops T cell-activating cancer
immunotherapies and other vaccine candidates based on DepoVax™, the
Company’s patented platform that provides controlled and prolonged
exposure of antigens and adjuvant to the immune system.
Immunovaccine has advanced two T cell activation therapies for
cancer through Phase 1 human clinical trials and is currently
conducting a Phase 1b study with Incyte Corporation assessing lead
cancer therapy, DPX-Survivac, as a combination therapy in ovarian
cancer. The Company is also exploring additional applications of
DepoVax, including DPX-RSV, an innovative vaccine candidate for
respiratory syncytial virus (RSV), which has recently completed a
Phase 1 clinical trial. Immunovaccine also has ongoing clinical
projects to assess the potential of DepoVax to address malaria and
the Zika virus. Connect at www.imvaccine.com.
Immunovaccine Forward-Looking
StatementsThis press release contains forward-looking
information under applicable securities law. All information that
addresses activities or developments that we expect to occur in the
future is forward-looking information. Forward-looking statements
are based on the estimates and opinions of management on the date
the statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Company, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Contacts for Immunovaccine:
MEDIA
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONS
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: info@imvaccine.com
Patti Bank, Managing Director, Westwicke Partners
O: (415) 513-1284
T: (415) 515-4572 E: patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024